3 July 2023 - Celltrion USA today announced the launch of Yuflyma (adalimumab-aaty), a high concentration (100 mg/mL) and citrate-free formulation of Humira (adalimumab) biosimilar, providing an alternative option for patients.

First approved by the FDA on 23 May 2023, Yuflyma became commercially available among key distributors across the US on 2 July.

Read Celltrion press release